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                                                                        INTRODUCTION
“For all the happiness that mankind can
gain it is not in pleasure but in relief from pain”
-JOHN DYRDEN
Pain is a fundamental biological phenomenon. The International Association for the study of 
pain has defined pain as an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage. Pain is always underestimated and under treated. The relief of pain during 
surgery is the main part of anaesthesia.
The most important duty of an anesthesiologist lies in providing relief from pain throughout the 
intra operative period. Extending the pain relief into the post operative period is necessary for both 
physiological and psychological well being of the patient.
The spinal cord has taken the centre stage in analgesia practice following the demonstration of 
analgesia  with  intrathecal  morphine  by  Yaksh  and  Rudy  (1977).  Deposition  of  drugs  in  the 
subarachnoid space and epidural space paved a new era for pain relief.
Present  study is  for  comparing  the  efficacy of  midazolam and fentanyl  when administered 
intrathecally in association with bupivacaine.
AIM OF STUDY
To evaluate and compare the efficacy of intrathecally administered midazolam and fentanyl in 
combination with hyperbaric bupivacaine with respect to the time of onset, duration of sensory block, 
quality of intraoperative anaesthesia, duration of effective postoperative analgesia and incidence of side 
effects.
REVIEW OF LITERATURE
1. Mac Donald R.L. and Young A.B in 1981 demonstrated GABA mediated inhibition of the spinal 
cord neurons in vivo and in primary dissociated cell culture.
2. In 1990 Wal dovel H.J and coworkers conducted a study on the regional cellular and subcellular 
distribution of GABA and benzodiazepine receptors. The highest density of GABA receptors and 
benzodiazepine receptors are localized as a dense band within lamina II of the dorsal horn with 
moderately high concentration in lamina I and III.
3. Nishiyama et al in 1992 used epidural midazolam in varying doses along with bupivacaine for pain 
relief in 47 patients who underwent upper abdominal surgery and it was concluded that the optimal 
dose of midazolam in epidural for postoperative analgesia without producing significant sedation 
was 0.05 mg/Kg.
4. Serrao J.M and coworkers in 1992 did a comparative study on the effects of intrathecal midazolam 
and intrathecal steroids for the treatment of chronic mechanical low backache.  Both treatments 
caused a significant pain relief in 50-75% of patients. But the use of self administered analgesics 
was less with midazolam group than the steroid group.
5. In 1994 Australian Society for Clinical Experimental Pharmacologists and Toxicologists conducted 
a study on the GABA receptors and demonstrated the presence of non A non B GABA receptors. 
These were known as Novel receptors.
6. In 1996 Valentine J.M and coworkers compared the postoperative analgesia provided by intrathecal 
bupivacaine,  intrathecal  bupivacaine and morphine,  intrathecal  bupivacaine and midazolam and 
intrathecal bupivacaine and morphine and midazolam in patients undergoing caesarean sections. 
The use of patient controlled analgesia was greater with plain bupivacaine group and patients given 
intrathecal morphine had pruritus.  The intrathecal midazolam provided useful analgesia without 
side effects. 
7. Clinical  Journal  for  Pain,  1996 March,  states  that  epidural  and  intrathecal  midazolam is  more 
effective against somatic pain.
8. In 1998 Nishiyama and coworkers observed the in vitro changes in the transparency and pH of CSF 
caused by adding midazolam and bupivacaine to saline. CSF pH and transparency were not altered 
by adding 5mg of midazolam in10ml of saline. 
9. A study was conducted in Department of Anesthesiology and Intensive care, All India Institute of 
Medical Sciences, New Delhi, India by Bharti N, Madan R, Mohanty P.R, Kaul H.L which was 
published  in  Acta  Anaesthesio  Sand.  2003,  about  the  antinociceptive  action  of  intrathecal 
midazolam.
They randomly selected two groups and gave 15mg of bupivacaine in one group and 15mg of 
bupivacaine and 1mg of midazolam for another group. They concluded that addition of intrathecal 
midazolam to bupivacaine significantly improved the duration and quality of spinal anaesthesia and 
provided prolonged postoperative analgesia without significant side effects.
10. A study was conducted  in  Department  of  Anesthesiology,  Samsung Medical  Centre,  Korea  by 
M.H.Kim and Y.M.Lee which  was published  in  British Journal  of  Anesthesia  2001,  about  the 
potentiation of analgesic effect of intrathecal bupivacaine by intrathecal midazolam.
These  groups  of  patients  were  randomly  allocated  and  control  group  received  5mg  of 
bupivacaine  and 0.2ml  of  0.9%saline,  second group received  5mg of  bupivacaine  and 1mg of 
midazolam and third group received 5mg of bupivacaine and 2mg of midazolam. They concluded 
that time to first analgesia was significantly greater in the midazolam groups than in the placebo 
and significantly less in the patients with the second group than in the third.
11. A  comparative  study  of  intrathecal  midazolam  and  bupivacaine  with  midazolam  for   postop 
analgesia  was conducted in Mahatma Gandhi Institute of Medical Sciences   by Dr.Ravikumar, 
Dr.Domkendur and Dr.S.Dhawade.
They randomly allocated two groups, Group M and Group B each with 50 patients. Group B 
received 20mg of bupivacaine and Group M received 10mg of bupivacaine and 1mg of midazolam 
intrathecally.  They concluded that  addition of midazolam to bupivacaine intrathecally provided 
better postoperative analgesia without any adverse effect.
12. A study about  effect  of midazolam with intrathecal bupivacaine for vaginal hysterectomy was 
conducted by Neeraj  Bharti,  R.Madan, R.P.Mahanty at  All  India Institute of Medical Sciences, 
New Delhi.
They selected 60 ASA I and II female patients undergoing vaginal hysterectomy and randomly 
allocated them into 3 groups. Group A received 3ml of 0.5% bupivacaine, Group B received 2.5ml 
of 0.5% bupivacaine with 1mg of midazolam in 0.5ml of normal saline and Group C received 2ml 
of  bupivacaine with 2mg of  midazolam in 0.5ml of  normal  saline.  They observed duration  of 
sensory,  motor,  perioperative analgesia along with hemodynamic variability and sedation.  They 
concluded that intrathecal midazolam can be used as bupivacaine sparing drug especially in elderly 
and  high  risk  patients  to  reduce  the  hemodynamic  variability  and  to  increase  postoperative 
analgesia.
13. A  study  of  comparative  evaluation  of  intrathecal  bupivacaine  and  intrathecal  bupivacaine 
midazolam combination on postoperative analgesia was done at Maulana Azad Medical College 
and  Lok  Nayak  Hospital,  New  Delhi  by  Dr.Nitesh  Agarwal  and  Dr.Bhadma.  They  randomly 
divided the patients into two groups, 25 patients in each group. Group B received 3ml [15mg] of 
0.5% bupivacaine  with  0.2ml  of  normal  saline  and  Group  BM  received  3ml  [15ml]  of  0.5% 
bupivacaine  and  0.2ml  [1mg]  of  midazolam.  They  concluded  that  combination  of  intrathecal 
midazolam and bupivacaine provides longer duration of postoperative analgesia as compared to 
intrathecal bupivacaine alone.
14. Works of Matan in 1900 combining morphine with intrathecal cocaine appears to be one among the 
first attempt to enhance spinal anaesthesia with spinal opioids.
In 1901 two independent reports,  one by a Japanese anaesthesiologist  and the second by a 
Romanian Surgeon, had been published as opioids for intrathecal anaesthesia.
In 1965 Gate control theory of pain proposed by Melzack and Wall focused on the importance 
of dorsal horn of spinal cord in the modulation of pain.
In 1973 Pert  and Snyder  identified  specific  opiate  receptors  in  the  substantia  gelatinosa  of 
dorsal horn of spinal cord.
In 1976 Yaksh and Reddy suggested that intrathecal opioids act at the presynaptic receptors in 
the substantia gelatinosa and block the release of neurotransmitters.
This study was undertaken in rats.
In 1980 Danir et al identified that respiratory depression due to intrathecal
morphine was reversed by naloxone without reversing analgesia.
In  1984  Huand  H.J,  Ishimain  T,  Yambe  studied  the  use  of  intrathecal  morphine  for 
postoperative pain relief.                                                                                      
15. A study of effect of intrathecal fentanyl added to hyperbaric bupivacaine for caesarean section was 
conducted at  Department  of  Anaesthesiology,  Tokyo University School  of  Medicine,  Tokyo.24 
patients posted for elective caesarean section were allotted to receive either 15mcg of fentanyl or 
0.9% normal  saline added to  2ml  of  0.5% hyperbaric  bupivacaine intrathecally in  right  lateral 
decubitus position. They concluded that addition of fentanyl to intrathecal bupivacaine in parturient 
undergoing caesarean section improved quality of anesthesia without producing side effects.
16. A study conducted by Dr.Biswas, Dr.Nath, Dr.Bhattacharjee was published in Indian Journal of 
Anaesthesia 2002 about intrathecal fentanyl added to hyperbaric bupivacaine improving analgesia 
during caesarean section and early postoperative period.
               They randomly allotted 40 parturients coming for elective caesarean section into two groups. 
Group  1  received  2ml  of  0.5%bupivacaine  with  0.25ml  of  0.9%saline.Group  2  received  2ml  of 
0.5%bupivacaine with 0.25ml (12.5mcg) of fentanyl.They concluded that 12.5mcg of fentanyl added to 
intrathecal bupivacaine could markedly improve intraoperative anaesthesia and significantly reduce the 
demand for postoperative analgesia with good maternal satisfaction and fetal well being.
17. A comparative study of intrathecal hyperbaric bupivacaine with fentanyl and bupivacaine alone for 
urological surgeries was done by Dr.Saravanan, Dr.Madankumar, Dr.Balamanimukizhan at Madras 
Medical College, Chennai. 80 patients posted for elective urological surgeries were allotted into 4 
groups with each group containing 20 patients.
Group A received 10mg hyperbaric bupivacaine and 0.5ml of distilled water intrathecally
Group B received 10mg hyperbaric bupivacaine and 0.5ml (25mcg) of fentanyl
Group C received 7.5mg of hyperbaric bupivacaine, 0.5ml of distilled water and 0.5ml (25mcg) 
of fentanyl
Group D received 5mg of hyperbaric bupivacaine, 25mcg of fentanyl and 1ml of distilled water.
They concluded  that  addition  of  25mcg  of  fentanyl  to  0.5%hyperbaric  bupivacaine 
markedly prolongs the postoperative analgesia without side effect. It also facilitates the use of 
smaller doses of bupivacaine in subarachnoid space.
HISTORY
SUB ARACHNOID BLOCK:
The first neuraxial block was performed by James Leonard Corning, who also coined the 
term “Spinal  anaesthesia” on October  12; 1865.He injected cocaine 120mg between T11 and T12 
spinous process, and obtained loss of sensation due to epidural block rather than a subarachnoid block.
Further  advances  took  place  in  Keil,  Germany where  August  Bier  and  his  assistant 
August Hilderbrant used Quinke’s method to enter the intrathecal space and injected 5-15mg of cocaine 
to produce spinal anaesthesia. This happened on August 16, 1898.
This  was  followed  by  successful  and  enthusiastic  practice  of  spinal  anaesthesia  by 
others:
• J.B Selclowitsch of St.Petersburg on May 11, 1899
• Theodre Juffier in France on November 9, 1899 and
• Rudolph Mates in New Orleans in November 10, 1899.
Barker advised meticulous sterile technique and introduced hyperbaric solutions.
Serious complications from spinal anaesthesia were soon observed. In 1900, F.Gumprecht observed 15 
cases of sudden death from lumbar puncture.
 After an infamous malpractice trial in 1953 ,which saw healthy patients developing spastic 
paraparesis after spinal anaesthesia ,came a reassuring study of 10,098 spinal anaesthesia with only 71 
minor neuropathies in 1954. This allowed spinal anaesthesia to emerge as a safe anaesthetic technique.
LOCAL ANAESTHETICS:
1855 : Friedrich Gaedicke of Germany isolated the first local anaesthetic 
agent cocaine.
1860 : Albert Neimann purified and named the alkaloid as cocaine.
1884 :    Carl Koller an opthamalogist from Vienna demonstrated the local 
analgesic properties of cocaine on the cornea.
William Halstead recognized the ability of injected cocaine to 
interrupt nerve impulse conduction, leading to the introduction of 
peripheral nerve block anaesthesia and spinal anaesthesia.
1885 :    J.L.Corning produced analgesia by neuraxial injection of  
cocaine.
1904 : Ernest Foureau synthesized stovaine.
1905 : Einhorn introduced the first synthetic local anaesthetic, 
procaine.
1943 :  Lofgren synthesized the first amide local anaesthetic 
lidocaine.
1947 :  Torsten Gordh made the first clinical use of lidocaine.
1957 :  Ekenston et al of Sweden synthesized bupivacaine.
1963 :  L.J.Tulivuo first used bupivacaine, clinically.
OPIOIDS:
1803 :  Morphine was isolated from opium by Serturner.
1832 :  Codeine was isolated.
1848 :  Papavarine was introduced.
1939 :  Meperidine was synthesized and it was used for anaesthesia with 
nitrous oxide.
1942 :  Nalorphine a mixed agonist-antagonist was introduced.
BENZODIAZEPINES:
Benzodiazepines were discovered  to be effective sedative and hypnotic drugs.
1955 :  Sternbach synthesized chlordiazepoxide.
1959 :  Sternbach synthesized diazepam.
1961 :  Oxazepam, a metabolite of diazepam was synthesized by Bell.
1971 :  Lorazepam was introduced. It was the first clinically used water 
soluble benzodiazepines.
1977 :  Specific receptor for benzodiazepines was identified.
Midazolam was the first benzodiazepine that was produced primarily for use in anaesthesia.
ANATOMY OF SUBARACHNOID SPACE
Subarachnoid  local  anaesthetics  effect  their  sensory  block  at  the  spinal  cord,  which  is 
continuous cephalad with the brain stem via foramen magnum and terminates distally in the conus 
medullaris. The distal termination, because of differential growth rates between bony vertebral canal 
and central nervous system, varies from L3 in the infant to L 1 in the adult.
Surrounding the spinal cord in the bony vertebral column are three membranes (from within to 
periphery):  the piamater,  subarachnoid mater and duramater.  The piamater is a highly vascularised 
membrane  that  closely  invests  the  spinal  cord.  The  arachnoid  mater  is  a  delicate  non  vascular 
membrane closely attached to the outermost layer, the duramater. Between these two innermost layers 
is the space called as subarachnoid space. In this space are the CSF, spinal nerves, a trabecular network 
between two membranes, blood vessels that supply the spinal cord and the lateral extensions of the 
piamater and the dentate ligaments, which provide lateral support from the cord to the duramater.
Although the spinal cord ends at L1,   the subarachnoid space continues to S2.  The third and the 
outermost layer in the spinal cord is the longitudinally organized fibroelastic membrane, the duramater. 
This layer is  the direct  extension of the cranial  dura and extends as spinal dura from the foramen 
magnum to S2, where the filum terminale blends with the coccyx.
PAIN – PHYSIOLOGICAL CONSIDERATION
Pain which may serve a number of useful  defensive functions, when associated with actual or 
potential tissue damage, can be an unpleasant sensory and emotional experience. Relieving pain is one 
of the most tangible roles the anaesthesiologist can play.
There are two major theories of pain:
1. Specificity theory proposed by Vonfrey states that pain is due to stimulation of specific end 
organs.
2. Intensive / Summation pattern theory proposed by Scheides states that there are no specific 
pain receptors and any sensory stimulus if sufficiently severe would produce pain.
NEUROANATOMY:
Painful stimuli which can be mechanical, thermal, electrical or chemical activate specific 
nociceptors  in  the  tissues.  Nociceptive  receptors  are  fine,  profusely  branched  free  nerve  endings 
covered by Schwann cells with little or no myelin. 
Receptors are of two types.
One  group  responds  to  mechanical  deformation  and  are  described  as  high  threshold 
mechanoceptors and others  respond to  a variety of  noxious  inputs  and are  polymodal  nociceptors. 
These receptors responds to mechanical, thermal and chemical stimuli like H + ,K+,histamine, serotonin, 
bradykinin, prostaglandin and substance P.
Fibre type Aδ finely myelinated ‘C’unmyelinated
Diameter
Conduction velocity
Distribution
Character of pain
Effect
2 – 5 μm
5 -15 ms-1
Body surface, muscles and 
joints.
Sharp and pricking pain
Felt quickly, well localized 
withdrawal reflex.
0.3 – 1.3 μm
0.5 – 2 ms-1
most tissues.
Delayed Diffuse dull 
aching.
Threshold for response is 
higher.
PRIMARY AFFERENT CONDUCTION:
The cell body of these nerve endings lies in the dorsal root ganglia. Central terminations of 
these fibres are in the dorsal horn of the spinal cord. Majority of the fibres enter into the spinal cord 
dorsal  horn  in  the  ventrolateral  bundle.  On entering  the  cord  the  roots  divide  into  ascending  and 
descending branches which may enter the dorsal horn one or two segments above or below the segment 
of origin.
DORSAL HORN OF THE SPINAL CORD:
Dorsal horn of the cord is divided into laminae on the basis of their histological appearance. 
There are numerous connections between the laminae although they do have discrete functions related 
to  pain processing.  Laminae II,  the substance gelatinosa,  extends from the terminal  nucleus in  the 
medulla to the filum terminale, C fibres terminate in lamina II. Aδ fibres terminate in lamina I and 
lamina V. Aβ fibres terminate in lamina I and lamina V. Aβ fibres which respond to innocuous stimuli 
such a vibration and light touch enter the cord medial to the dorsal horn and pass without synapse to the 
dorsal  column.  They  give  off  collateral  branches  to  the  dorsal  horn  which  terminate  in  laminae 
particularly III and IV and deeper. They also synapse directly with terminals of unmyelinated C fibres 
in lamina II.  The laminae that receive afferent input from both large and small diameter fibres are 
important  sites  for  pain  modulation  and  localization.  From lamina  III  and  deeper,  information  is 
summated from direct input from the periphery and from dorsal laminae.
The extent to which painful peripheral stimuli are conducted centrally and perceived as pain 
depends upon the degree to which two major modulating mechanisms at the level of dorsal horn close 
the gate to onward transmission.
The Gate Control Theory proposed by Melzack and Walls:- 
1. Activity of large myelinated Aβ fibres is via inhibitory circuits in the superficial laminae of 
the dorsal horn to suppress the transmission in small unmyelinated ‘C’ afferents.
2. Inhibitory control from higher centres is tonically active. From the dorsal horn, nociceptor 
neurons  ascend  in  the  contralateral  spinothalamic  and  spinoreticular  tracts  in  the 
anterolateral white matter of the cord.
The spinothalmic tract principally comprises of axons of neurons in lamina I and V of the dorsal 
horn, in which most of the Aδ fibres terminate. These ascend to the central posterior lateral nucleus of 
the thalamus and thence to the post central gyrus. Axons are somato topically organized, with caudal 
elements found laterally and those from the rostral structures  arranged centrally, in the nerve. The 
spinothalmic tract sends collateral branches to the periaqueductal grey matter in the mid brain.
The  spinoreticular  pathway arises  from cells  deeper  in  the  grey matter  of  the  dorsal  horn 
including lamina V. Fibres ascend in the anterolateral  cord and reach the nuclei  of the brain stem 
reticular formation,  whence they project  to  the thalamus,  hypothalamus and thalamic inter  laminar 
nucleus.  The  later  project  diffusely  to  the  whole  of  the  cerebral  cortex.  This  system shows little 
somatotopic organisation and is involved in the perception of diffuse emotionally disturbing pain.
DESCENDING INHIBITORY PATHWAYS:
These  cause  modulation  of  pain  perception.  Electrical  stimulation  of  periaqueductal  grey 
produce profound analgesia, but responses to non noxious stimuli  remains normal and subjects are 
alert.  Injection  of  morphine  in  this  region  produces  greater  analgesic  effect.  Periaqueductal  grey 
receives input from thalamus, hypothalamus, cerebral cortex and collaterals from spinothalmic tract. 
So, it is an important centre for descending control of pain. It projects into nucleus raphe magnum in 
the medulla. Axons from the nucleus descend in the dorsolateral funiculus of the spinal cord to the 
dorsal horn.
OTHER INHIBITORY PATHWAYS:
1. Large primary afferent fibres:
A§ fibres with cell bodies in the dorsal root ganglia send their central projections 
ascending in the dorsal column. They send collaterals to synapse with and activate inhibitory 
inter neurons which inhibit release of transmitter along pain pathways.
2. Endogenous opiates:
Encephalin, bendesphir and dynorphins, are derived from biologically inactive 
peptide  precursors  produced  in  cell  body  of  neurons  and  transported  to  axon  terminal. 
Distributed widely in central nervous system, but particularly in sites associated with pain. They 
act as endogenous ligands for opioid receptors producing primary inhibitory effects.
      
3. Amines:
Noradrenaline is involved in descending modulation of pain, probably acting via 
α2  receptor.  Serotonin is also involved in descending modulation of pain. All serotonin receptor 
subtypes are probably involved.
4. GABA:
Evidence strongly suggests that GABA mediates the inhibitory action of local 
interneurons in the brain and it mediates presynaptic inhibition within the spinal cord.
FUNCTIONS OF PAIN CENTRES:
Thalamus- experience of  pain is  the main function.  The post  central  gyrus  is  for accurate 
localization of pain. The prefrontal cortex produces affective unpleasant reaction to pain. Fast and slow 
conductance explains the double sensation of pain following brief painful stimulus. More distal the 
stimulus more distinct can two successive peak be felt.
MEDIATORS OF PAIN:
Peripheral  mediators  are  prostaglandin  E  & I,  autocoids  such  as  bradykinin,  acetylcholine, 
histamine, 5 hydroxytryptamine, leukotrienes and cytokines.
Brain  and  spinal  cord  mediators  are  substance  P-the  principle  transmitter,  hydrogen  ions, 
vasoactive  intestinal  polypeptide  glutamate  and  aspartate.These  mediators  cause  distortion  of  the 
terminal  region  of  neurons,  modifying  the  ion  permeability  and  interfering  with  propagation  of 
impulses.
ADJUVANTS TO LOCAL ANAESTHETICS IN SPINAL ANAESTHESIA
Local  anesthetic  agents  have  been  widely  used  in  spinal  anaesthesia.One  of  the  main 
disadvantage  is  the  limited  duration  of  block  achieved  with  local  anaesthetics.To  overcome  this, 
various adjuvants have been tried and used successfully. This addition of adjuvant has further expanded 
the advantage of regional anaesthesia over general anaesthesia.
ADJUVANTS:
These  may  be  opioids  like  morphine,  fentanyl,  sufentanil  or  buprenorphine.  It  may  be 
benzodiazepines alpha 2 agonist clonidine, acetylcholine esterase inhibitors like neostigmine, NMDA 
receptor antagonist ketamine or nonsteroidal anti inflammatory agents.
These adjuvants usually confer the advantages of 
• Rapid onset time
• Differential blockade
• Inhibition of tourniquet pain
• Improved and prolonged duration of post operative analgesia.
Also these adjuvants decrease the amount of local anesthetic required to produce same effect 
thereby reducing the risk of local anesthetic toxicity, hypotension and profound motor blockade.
OPIOIDS
The term opioids refer to all compounds related to opium, derived from juice of opium poppy, 
papaver  somniferum.  Opiates  are  the  term  used  for  drugs  derived  from  opium.  Morphine  is  the 
prototype  opioid.  Opioid  compounds  can  be  classified  as  naturally  occurring,  semisynthetic  and 
synthetic opioids. With the development of synthetic drugs with morphine like effects, the term opioid 
is now used to refer to all exogenous substances, natural and synthetic that binds to opioid receptors 
and produces some agonistic effects.
CLASSIFICATION:
Naturally occurring opioids are divided into two chemical classes
1. Phenanthrenes-eg. Morphine and codeine
2. Benzylisoquinolones-eg. Papavarine
Semisynthetic  opioids result  from  relatively  simple  modification  of  morphine 
molecule.eg.diacetylmorphine.
Synthetic opioids contain phenanthrene nucleus. They are classified into four subdivisions.
1. Morphinan derivatives-eg.levorphanol
2. Methadone derivatives-eg.methadone
3. Benzomorphan derivatives-eg.pentazocine
4. Phenylpiperidine derivatives-eg.meperidine, fentanyl, sufentanil, alfentanil
OPIOID RECEPTORS:
The presence of opioid binding sites  in the nervous system was reported in the year  1973. 
Immuno  histochemical  studies  have  demonstrated  opioid  receptors  in  various  areas  of  the  central 
nervous system. These indude the amygdala, the mesencephalic reticular formation, the periaquiductal 
gray matter and the rostral ventral medulla. 
Based on pharmacological experiments three types of opioid receptors were published.
(i) mu or µ for morphine type 
(ii) Kappa or K for Ketocyclazocinetype 
(iii) Sigma or σ for SKF 10047 type
In addition two other receptors have been indentified in the vas deferens of mouse namely the 
delta (σ) and epsilon (∑) receptors. All the receptors bind to a super family guanidine protein coupled 
receptors. 
The mu or morphine preferring receptors are principally responsible for supra spinal and spinal 
analgesia. Various subtypes have been proposed based on post translational modification of µ  receptor. 
µ1 rceptor  is  speculated  to  produce  analgesia,  while  µ2 receptor  is  responsible  for  hypotension, 
bradycardia and respiratory depression. Delta receptors serve to modulate the activity of  µ receptor. 
Kappa  receptors  are  those  to  which  most  of  the  opioid  agoinst  –  antagonist  bind.  Respiratory 
depression is less common with Kappa receptor activation than µ. Dysphoria and diuresis may occur. 
High intensity painful  stimulations are resistant to the analgesic effect of Kappa receptor activation.
                        CHARACTERISTIC OF OPIOID RECEPTORS
Mu (µ1) Delta ( σ ) Kappa (K)
1 Endogenous Ligand β-endorphin endomorphine
Leu-enkephalin 
Metenkephalin
Dynorphin
2 Agonist
Morphine            
  Fentanyl
DPDPE 
Deltorphin
Buprenorphine 
Pentazocine
3 Antagonist
Naloxone 
Naltrexone
Naloxone 
Naltrindole
Naloxone   Nor 
BNI
4 Coupled G Protein G i/o G i/o G i/o
5 Adenylate cyclase Inhibition Inhibition Inhibition
6 Effect
Analgesia
Supraspinal and spinal (µ1)
Euphoria (µ1)
Respiratory
Depression (µ2)
Bradycarrdia (µ2)
Constipation (µ2)
Analgesia
Respiratory
Depression
Constipation
(minimal)
Analgesia
(Spinal)
Dysphoria
Sedation
Miosis
Diuresis.
PHARMACOLOGICAL ACTIONS OF OPIOIDS
Receptor ActionAgonists Antagonists
1
Supraspinal 
Spinal
µ,  σ, k
µ,  σ, k
Analgesic
Analgesic
No effect
No effect
2.
Respiratory 
function
µ Decrease No effect
3.
Gastro intestinal 
tract
µ, k Decrease transit No effect
4. Psychotomimesis k Increase No effect
5. Feeding µ,  σ, k Increase Decrease
6. Sedation µ, k Increase No effect
7. Diuresis k Increase -
8. 
Harmone 
secretion 
(a)Prolactin    (b) 
growth hormone
µ
µ and σ
Increase release
Increase release
Decrease 
release
Decrease 
Release
MECHANISM OF ANALGESIC ACTION:
Opioids act as agonists at stereospecific opioid receptors at presynaptic and post synaptic sites 
in the central nervous system and also outside central nervous system in peripheral tissues. 
MECHANISM OF ACTION IN CENTRAL NERVOUS SYSTEM:
The  analgesic  effect  of  opioids  results  from their  ability  to  directly  inhibit  the  ascending 
transmission of nociceptive information from the spiral cord dorsal horn. It has a descending inhibitory 
analgesic action by activation of pain control circuits that descend from the midbrain via the rostral 
ventromedial medulla (RVM) to the spinal cord dorsal horn. In addition, local spinal mechanisms also 
take part in the analgesic action of opioids.
Existence of the opioids in the ionized state is necessary for strong binding at the anionic opioid 
receptor site. Stereochemically, levorotatory  forms are found to be most active. The affinity of most 
opiod agonists for receptors correlated with their analgesic property.
The principal  effect  of  opioid  receptor  activation  is  a  decrease in  neuro transmission.  This 
decrease in  neuro transmission is  largely due to  presynaptic  inhibition of neurotransmitter  release, 
although post  synaptic  inhibition  of  evoked activity  may also occur.  The  neurotransmitters  whose 
release are also inhibited include acetylcholine, dopamine, norepinephrine and substance P.
The intracellular biochemical events activated by binding of opioid agoinst to opioid receptor 
are
(i) increased potassium conductance – leading to hyperpolarization
(ii) Calcium channel  inactivation
Both of which produce an immediate decrease in neurotransmitter release.
Opioid receptors mediated inhibition of adenylate cyclase, causing a decrease in cellular cAMP 
has  delayed  effect,  via  a  reduction  in  cAMP  responsive  neuropeptide  genes  and  a  reduction  in 
neuropeptide mRNA concentrations.
MECHANISM OF ACTION IN PERIPHERAL TISSUES:
Opioids are effective in inflammatory hyperalgesic conditions. The opioids bind to receptors in 
the primary afferent neurons and mimic the action of endogenous ligands, resulting in the activation of 
pain modulating (antinociceptive) systems.
EFFECT OF OPIOIDS ON VARIOUS SYSTEMS OF THE BODY:
These can be classified into therapeutic drug effects and non-therapeutic drug effects.
THERAPEUTIC DRUG EFFECTS:
OPIOIDS AS ANAESTHETICS:
The capacity of opioids to produce anesthesia is debated. General anaesthesia can be considered 
in terms of its component parts; amnesia, analgesia, unconsciousness, immobility, muscle relaxation 
and control of autonomic and endocrine responses  to surgery.
Of these, opioids produce effects  of analgesia, unconsciousness and control of autonormic and 
endocrine responses to surgery. Butorphanol has been reported to produce anterograde amnesic effect.
Shivering: Post anaesthetic shivering, that is unrelated to hypothermia can be effectively abolished by 
certain opioids like meperidine, butorphanol and tramadol.
CENTRAL NERVOUS SYSTEM:
Opioids generally produce modest  decrease in cerebral  methabolic rate (CMR). They cause 
decrease in cerebral blood flow when co administered with nitrous oxide and a cerebral vasodilating 
anaesthetics.  Opioids  affect  intracranial  pressure minimally,  but  may cause  increase  in  intracranial 
pressure when compliance is compromised.
NON THERAPEUTIC DRUG EFFECTS:
While opiods have proved to be relatively safe drugs,management of side effects is critical to 
successful application in clinical practice.
RESPIRATORY EFFECTS:
Opioids  decrease  resting  minute  ventilation  and  tidal  volume.  Respiratory  rate  may  be 
decreased or normal, whereas  µ agoinsts produce a dose related depression of breathing. Ventilatory 
responses  to  hypoxia  and hypercarbia  are  blunted.  Sufficient  doses  may produce,  apnoea,  but  the 
apnoeic conscious patient may breathe on command.
CARDIOVASCULAR EFFECTS:
The action of opioids on cardiovascular system is mostly due to histamine release. Morphine or 
meperidine which cause release of histamine provide hypotension and tachycardia.
Opioids also depress contractility of isolated heart muscle, but at doses greatly in excess of 
those  used  clinically.  An exception  to  this  is  meperidine  which  produce  myocardial  depression  at 
clinically  relevant  concentrations.  Morphine  and  fentanyl  analogs  decrease  heart  rate  due  to 
vagominetic action. On the otherhand, meperidine, due to its anticholinergic properties increase heart 
rate.
RIGIDITY:
Opioid induced muscle rigidity occurs usally during induction of anaesthesia, especially with 
largers doses. This rigidity is central in origin, being mediated by µ receptors in brainstem medulla. 
NEUROEXCITATORY EFFECTS:
Opioids are also associated with tonic – clonic movements or myoclonus.
GASTRO INTESTINAL EFFECTS:
These effects manifest by a combination of central and peripheral actions. The effects observed 
are decrease in intestinal motility and increase in the tone of  sphincter of Oddi.  Nausea and vomiting 
is a commonly observed effect of opioids due to its stimulation of receptors at chemoreceptor trigger 
zone.
PRURITIS:
It is a common opioid-induced side effect, especially with neuraxial opioids.
INTRATHECAL OPIOIDS
In  the  context  of  “Augmentation  strategies”  for  spinal  anaesthesia,  the  discovery of  opioid 
receptors and the development of technique of intrathecal opioid administration is one of the most 
significant advances in pain management in the last three decades. Plethora of studies have shown that 
spinal opioids can provide profound post operative analgesia with fewer neurological and systemic side 
effects than with systemic opioids. This is because neuraxial opioids, in contrast to local anaesthetics, 
do not cause sympathetic block, skeletal muscle weakness or lack of proprioception.
BRIEF HISTORY:
In 1900, Matas discovered that the adverse effects of intrathecally administered cocaine could 
be mitigated with the addition of morphine. He used 1.5mg morphine intrathecally to reduce the central 
nervous system effects of cocaine.
In  1901,  a  Japanese  anesthesiologist  Otojiro  Kitagawa,  used  10mg of  morphine  with  local 
anaesthetic eucaine intrathecally for cancer pain relief.
With  the  discovery of  opioid receptors  in  the  spinal  cord,  intrathecal  opioid administration 
quickly spread to perioperative care in a wide array of surgical procedures.
PHARMACODYNAMICS:
The exact mechanism of local anaesthetic – opioid interaction remains unkown, despite detailed 
characterization of opioid receptor system at the cellular and molecular level.
When administered alone,  spinal opioids selectively modulate C and A fibres with minimal 
impact  on dorsal  root axons.  Somatosensory evoked potentials  remain intact  with respect  to  nerve 
conduction block. None of the opioids exhibit local anaesthetic property except possibly meperidine.
Local anaesthetics potentiate the antinociceptive effect of morphine, without an enhancement in 
motor block. Transient change in temperature perception has been observed with spinal meperidine, 
fentanyl and sufentanil.
The dorsal root entry zone is speculated to be the active site for conduction block for spinal 
opioids. The hormonal milieu (pregnancy) also contributes to drug effectiveness. Spinal progesterone 
has been found to potentiate the analgesic effects of spinal sufentanil in rats.
PHARMACO KINETICS:
It is believed that hydrophilic opioids remain unbound in the CSF for a long time and hence to 
move rostrally in the CSF, thereby resulting in delayed respiratory depression. (eg) morphine.
In  contrast  lipophilic  opioids  do  not  move  rostrally  in  CSF,  but  move  more  rapidly  than 
hydrophilic  opioids from CSF to spinal  cord.  But recently,studies have shown that  even lipophilic 
opioids do not remain localized near their site of injection and they may rapidly move from lumbar 
intrathecal injection sites to cervical and brain stem levels via CSF.
ONSET OF ACTION:
Lipophilic opioids spread more rapidly from the CSF into the spinal cord. Hence they have 
faster onset of action (eg.fentanyl) than hydrophilic opioids. The delayed onset of action of morphine, a 
hydrophilic opioid may in fact limits its utility as an intra operative adjuant.
ANALGESIC MECHANISMS:
The effect of intrathecally administered opioids are determined by the pharmacodynamics and 
pharmacokinetics of each individual drug. The dorsal horn of the spinal cord is richly populated with 
opioid receptors. Majority of these are localized within substansia gelatinosa. Upon receptor activation, 
a G protein mediated effects result in inhibition of adenyl cyclase and inward flux  of potassium. This 
flux results in membrane hyperpolarization and decrease in neural excitability (anti nociceptive effect). 
Opioids may act at synapses in spinal cord either presynaptically or postsynaptically.
µ receptor activation results in the presynaptic inhibition of substance P release, a compound 
that would otherwise result in the activation of an integrated pain signal.
All clinically useful intrathecal opioids are strong  µ receptor agoinsts within the dorsal horn. 
Their supra spinal and spinal effects act synergistically to blunt somatic as well as visceral pain. But 
analgesic effect is more specific for visceral pain. Analgesia of neuraxial opioids is also dose related. 
DURATION OF ACTION:
The duration of analgesic action will depend upon the efficacy, lipophilicity, receptor affinity 
and the dose of the drug administered. Less lipid soluble drugs (eg morphine) will remain in the CSF 
for a longer time and hence will produce longer duration of analgesia than a highly lipophilic opioid 
like fentanyl.
High lipophilicity favours more rapid removal of the drugs from the receptor site into the blood 
stream, which limits the duration of action, only exception to this being buprenorphine.
POTENCY:
H.J.MCQuay et al in 1989 published that the intrathecal potency is defined as the amount of 
drug required to produce a particular degree of receptor occupancy .It is inversely related to their  lipid 
solubility  and related  directly  to  the  affinity  of  the  drug  for  the  receptor.  The  inverse  correlation 
between intrathecal potency and lipophilicity may be due to the nonspecific binding of highly lipophilic 
agents to the lipid rich fibres capping the dorsal horn, limiting their access to the opioid receptors. 
Highly soluble opioid pethidine, is least potent and has to be used in systemic doses for intrathecal 
administration. 
SIDE EFFECTS:
Opioids  injected  into  the  lumbar  CSF  may  spread  passively  cephalad  by  diffussion  and 
concentration gradient effect, aided by arterial pulsation and respiratory movements over a time course 
of 6 – 8 hours. They may reach the vicinity of the cisterna magnum and brain tissue of fourth ventricle. 
This  explains  the  occurence  of  nausea,  vomiting  and  respiratory  depression  after  intrathecal 
administration.
Incidence of side effects is dose related and larger doses are clearly associated with  higher 
incidence of side effects.
NAUSEA AND VOMITING:
Opioids  commonly  produce  nausea  and  vomiting.The  vomiting  center  in  medulla  receives 
inputs from many centers including the chemoreceptor trigger zone, which contain opioid receptors 
among others, that promote vomiting. But it has been observed by Dahlgren et al that spinal opioids 
administred along with local  anaesthetics  in  spinal  anaesthesia  for cesarean sections  decreased the 
requirement of intraoperative antiemetic medication.
Cooper et al reported a significant reduction in intraoperative nausea with an addition of spinal 
fentanyl  to  a  spinal  anaesthetic  for  cesaerean  delivery.  The  effects  are  due  to  the  dense  sensory 
blockade achieved by the addition of opioids to local anaesthetics in spinal anaesthesia. 
PRURITIS:
It is a peculiar and the most common side effect with neuraxial opioids. It is not confined to the 
segmental area of analgesia, but may be generalized or localized to the face, neck or upper thorax. 
Pruritis is usually very mild, severe pruritis occurring in about 1% of patients. Pruritis is more likely to 
occur in obstetric patients, perhaps due to interaction of estrogen with opioid receptors.
Though  opioids  may  release  histamine  from  mast  cells,  this  is  not  the  mechanism  for 
pruritis.Pruritis  may be  due  to  a  generalized  modulation  of  cutaneous  sensation  or  in  the  case  of 
neuraxial opioids, due to cephalad migration of the opioid in the CSF and subsequent interaction with 
opioid receptors in the trigeminal nucleus. Pruritis may or may not be dose related.
URINARY RETENTION:
This  is  usually  encountered  with  hydrophilic  spinal  opioids.  Urinary retention  occurs  most 
likely due to  the  interaction  of  opioids  with opioid receptors  in  sacral  spinal  cord.  This  promotes 
inhibition of sacral parasympathetic nervous system outflow causing detrusor muscle relaxation and an 
increase in maximal bladder capacity. There is also an increase in vesical sphincter tone. All these 
factors results in urinary retention.  This effect is usually not dose related.
RESPIRATORY DEPRESSION:
 This is a major problem, limiting the use of spinal opioids. Respiratory depression may occur 
early or late. Early respiratory depression is usally mild, occur due to vascular uptake of drugs and 
occurs within one hour with morphine and within minutes with lipophilic opioids.
Late respiratory depression more problematic and occurs 4 – 18 hours following intrathecal 
administration.   This  is  due to  the  cephalad spread of  drug in  the CSF.  Highly lipophilic  opioids 
dissolve readily in neural tissue (segmental localization), thus limiting the drug available for cephalad 
spread. Hence, lipophilic opioids are considered safe with regard to late onset respiratory  depression. 
Factors which predispose to development of respiratory depression after intrathecal opioids are 
advanced  age,  high  risk  patients,  larger  dose  of  opioids,  use  of  hydrophilic  opioids,  intrathecal 
administration as  compared with epidural, concominant use of parenteral opioids or sedatives or both, 
opioid sensitive patients and thoracic epidural administration.
Obstetric patients are at lesser risk for ventilatory depression, perhaps because of the increased 
stimulation of ventilation  by progesterone.
SEDATION:
This effect is dose related and occurs with all opioids. Whenever sedation occurs, depression of 
ventilation should also be considered.
CENTRAL NERVOUS SYSTEM EXCITATION:
Tonic  skeletal  muscle  rigidity  resembling  seizure  activity  is  a  well  known  side  effect  of 
intravenous  opioids,  but  is  rarely  observed  with  neuraxial  opioids.  Myoclonic  activity  has  been 
observed after neuraxial opioids. A possible explanation for this effect is the cephalad migration of the 
opioid in CSF and subsequent interaction with non opioid receptors in the brain stem or basal ganglia. 
In this regard, opioids may block, glycine and gamma amino butric acid mediated inhibition.
ANTAGONISM:
 Systemically  administered  naloxone  can  antagonize  all  the  side  effects  of  spinal  opioids 
including respiratory depression.  Repeated doses may be required to maintain adequate ventilation. 
Prophylactic  administration of  naloxone has  also been recommended by some to  prevent  pruritus, 
nausea, vomiting and other side effects. Analgesic effect is usally affected by naloxone.
MERITS AND DEMERITS OF SPINAL OPIOIDS:   
MERITS:
- Greater success rate of spinal anaesthesia
- Faster onset of surgical block than local anaesthetic alone
- Improved intra operative analgesia (enhanced sensory block without increased motor block)
- Reduction in the dose of local anaesthetics with faster recovery from spinal anaesthesia
- Post operative analgesia beyond duration of local anaesthetic block
- Less nausea and vomiting
DEMERITS:
- Frequent pruritus
- Sedation (never with lipophilic opioids)
- Rare respiratory depression (especially late onset)
- Rare uninary retention (more with morphine)
- Nausea,vomiting, somnolence and early respiratory depression due to vascular uptake of 
opioids.  These are dose related. 
PHARMACOLOGY OF FENTANYL
Fentanyl is a phenyl piperidine derivative, synthetic opioid agonist that is structurally related to 
meperidine. As an analgesic fentanyl is 75 to 125 times more potent than morphine.
PHARMACODYNAMICS: 
A single dose of fentanyl administed intravenously has a more rapid onset and shorter duration 
of action than morphine. The effect- site equilibration time is 6.4 minutes. Rapid onset is due to its high 
lipophilicity and shorter duration of action is due to its rapid redistribution to inactive sites such as fat 
and  skeletal  muscles.  It  is  estimated  that  75%  of  initial  fentanyl  dose  is  undergoing  first-pass 
pulmonary uptake.  When funtanyl  is  administered in continuous infusion,  progressive saturation of 
these inactive tissue sites occur. As a resalt, the plasma concentration of fentanyl does not decrease 
rapidly. So the duration of analgesia, as well as depression of ventilation, may be prolonged.
PHARMACOKINETICS:
Fentanyl is extensively metabolized by N – demethylation, producing nor fentanyl, which is 
structurally similar to normeperidine. Nor fentanyl is excreted by the kidneys and can be detected in the 
urine for 72 hours after a single intravenous dose of fentanyl. Even though fentanyl has a short duration 
of action, its elimination half life is longer than that for morphine. This in infact due to a larger volume 
of distribution of fentanyl.  The larger volume of distribution is due to its greater lipid solubility and 
then more rapid passage of  drug into tissues compared with less  lipophilic  morphine.  The plasma 
concentrations of fentanyl are maintained by slow reuptake from inactive tissue sites, which account 
for its persistent effect.
CONTEXT SENSITIVE HALF TIME:
As the duration of continuous infusion of fentanyl increases beyond about 2 hours, the context 
sensitive  half-time  of  this  opioid   becomes  greater  than  sufentanil.  This  reflects  the  saturation  of 
inactive tissue sites with fentanyl during prolonged infusions and return of the opioid from peripheral 
compartments  to  the  plasma.  This  tissue  reservoir  of  fentanyl  replaces  the  fentanyl  eliminated  by 
hepatic metabolism so as to slow the rate of decrease in the plasma concentration of fentanyl when the 
infusion is stopped.
DURING CARDIO PULMONARY BYPASS:
 All opioids show a decrease in plasma concentration with the initiation of cardio pulmonary 
bypass. The degree of this decrease is greater with fentanyl because a significant proportion of the drug 
adheres to the surface of the cardiopulmonary bypass circuit. Sufentanil and alfentanil may provide a 
stable plasma concentration during cardio pulmonary bypass. Elimination of fentanyl and alfentanil are 
prolonged by cardio pulmonary bypass.
CLINICAL USES:
Low dose of fentanyl, 1- 2mcg / kg, is injected to provide analgesia. Moderate dose of fentanyl, 
2 – 20mcg/kg, is administered as an adjuvant to inhaled anaesthetics to blunt the circulatory responses 
to (a) direct laryngoscopic intubation (b) sudden change in the level of surgical stimulation. Timing of 
fentanyl administration to blunt these responses should consider the effect-site equilibration time.
Larger doses of fentanyl, 50 – 150mcg/kg have been used alone to produce surgical anaesthesia. 
The advantage of larger and sole fentanyl administration are (a) lack of myocardial depressant effect, 
(b) absence of histamine release,  (c)  suppression of the stress responses to surgery.  Disadvantages 
include (a) post operative depression of ventilation and (b) possible patient awarness.
Fentanyl may be administered as a oral transmucosal preparation in a delivery device designed 
to  deliver 5 – 20mcg / kg of fentanyl. In children  aged 2 to 8 years, the preoperative administration of 
transmucosal fentanyl 15-20mcg/.kg 45 minutes  before the induction of anaesthesia, reliably induces 
preoperative sedation and facilitates induction of inhalation anaesthesia. But there is more chance of 
post operative nausea and vomiting in these patients. 
Trensdermal fentanyl preparation delivering 75 to 100 mcg /hour result in peak plasma fentanyl 
concentrations for about 18 hours that tend to remain stable during the presence of the patch, followed 
by declining  plasma concentration for several hours after removal of the delivery system, reflecting 
continued absorption from the cutaneous depot. 
SIDE EFFECTS:
RESPIRATORY EFFECTS:
Persistent or recurrent depression of ventilation is a potential post operative problem. There are 
two theories for secondary peaks in plasma concentration of fentanyl. One is due to sequestration of 
fentanyl  in  acidic  gastric  fluid.  This  sequestered  fentanyl  could  then  be  absorbed  from the  more 
alkaline small intestine back into the circulation to increase the plasma concentration of opioid and 
cause  depression  of  ventilation  to  recur.  Second  is  due  to  washout  of  opioid  from the  lungs  as 
ventilation  perfusion relationships are reestablished in the postoperative period. 
CARDIOVASCULAR EFFECTS:
Carotid baroreceptor reflex control of heart rate is markedly depressed by fentanyl. Bradycardia 
is more prominent with fantanyl and may lead to occasional decreases in blood pressure and cardiac 
output. 
CENTRAL NERVOUS SYSTEM EFFECT:
Seizure  activity  has  been  described  to  follow rapid  intravenous  administration  of  fentanyl, 
sufentanil and alfentanil. In the absence of EEG, it is difficult to distinguish opioid –induced skeletal 
muscle  rigidity  or  myoclonus  from seizure  activity.  Opioids  may  produce  a  form  of  myoclonus 
secondary to depression of inhibitory neurons that could produce a clinical picture of seizure activity in 
the absence of EEG changes. 
Administration of   fentanyl  and sufentanil  to  head injury patients  has been associated with 
modest increase in intracranial pressure despite maintanence of an unchanged PaCO2. These increases 
in intracranial pressure are typically accompanied by decrease in mean arterial pressure and cerebral 
perfusion pressure. 
DRUG INTERACTIONS:
Analgesic concentration of fentanyl greatly potentiate the effects of midazolam and decrease the 
dose requirements of propofol. The opioid – benzodiazepine combination displays marked synergism 
with respect to hypnosis and depression of ventilation. 
PHARMACOLOGY OF MIDAZOLAM
Midazolam is an imidobenzodiazepine,  water soluble benzodiazepine.  Benzodiazepines were 
introduced in early 1960s. Diazepam, the most popular drug of this group for the past 2 decades, is 
water insoluble, has a prolonged effect and is painful during injection. The unique chemical structure of 
midazolam  confers  a  number  of  physiochemical  properties  that  distinguish  it  from  other 
benzodiazepines. This drug was synthesized in 1976 by Tryer and walser. 
CHEMISTRY:
 Benzodiazepines  are  so  called because they consist  of  a  benzene  ring  fused with a  seven 
member  diazepine  ring.  Various  modification  in  the  structure  of  the  ring  systems  have  yielded 
compounds with similar activities. 
Midazolam with molecular weight of 362, has a fused imidazole that is different from classic 
benzodiazepines.The imidazole ring accounts for the basicity, stability of an aqueous solution and rapid 
metabolism. The ring exhibits a pH dependent ring opening phenomenon. The ring opens at pH less 
than 4 making the drug soluble in aqueous solution. Once midazolam enters the body, the pH changes 
to 7.4 and drug assumes closed ring structure and becomes highly lipid soluble. Midazolam is the most 
lipid soluble benzodiazepine. 
PHARMACOKINETICS:
Midazolam is rapidly absorbed from gastro intestinal tract, but only 50% of the orally given 
drug enters the circulation, as substantial portion is metabolized during the first hepatic flow. Thus the 
oral dose is twice as high as intravenous dose.
Peak plasma concentrations are seen within an hour of ingestion.  When given intramuscularly, 
the absorption is more predictable than diazepam. Being highly fat soluble it crosses blood brain barrier 
more easily than diazepam, to gain access to the receptors. It has a more rapid most of action. After 
intravenous administration of midazolam to healthy adults the disappearance of midazolam from the 
plasma proceeds in two distinct phases. The initial phase of rapid disappearance is due to principally to 
distribution of the drug while the final and slower phases of disappearance is attributable mainly to 
biotransformation. Midazolam volume of distribution averages between 1 and 2.5 l/kg. Midazolam is 
tightly bound to plasma protein. After distribution equilibrium is reached elimination half-life varies 
from 1 to 4 hours. Midazolam is metabolized mainly by hepatic microsomal oxidative mechanism, by a 
process of hydroxylation. The fused imidazole ring is oxidized very rapidly to both 1 and  4 hydroxy 
midazolam. Both these products are conjugated to glucuronides and are excreted in the urine.  The 
Metabolites have less than 1% activity of the parent drug. 
FACTORS AFFECTING PHARMACOKINETICS:
Old age – Elimination half-life is increased and clearance is delayed. 
1. Obesity – The Volume of distribution is increased.This increases the elimination half-life, but 
there is no change in the total metabolic clearance. 
2. Renal insufficiency – As less than 1% of midazolam is cleared through the kidney, there is 
minimal alternation of its clearance in patients with renal insufficiency. The free fraction of 
midazolam in the plasma is increased due to decreased plasma binding. 
3. Pregnancy – Midazolam crosses the placental barrier, but the placental transmission as judged 
by foetal – maternal plasma ratio in animals is less for midazolam than for diazepam. 
4. Gender – males are more susceptible to midazolam than female patients.  
MECHANISM AND SITE OF ACTION:
An important inhibitory neurotransmitter in the brain is gamma amino butric acid (GABA), 
while  glycine  is  the  major  inhibitory  neurotransmitter  in  the  spinal  cord  and  brainstem.  The 
benzodiazepines augment GABA thus producing sedation and  anticonvulsant activity, while anxiolysis 
and muscle relaxation appear to be due to glycine mimetic effects in the spinal cord and brainstem.
Among the benzodiazepines midazolam has the greatest affinity for the receptors, but dissociate 
faster from the receptor, thus accounting for the rapid onset and shorter duration of action. Given 
intrathecally  or epidurally,midazolem produces analgesia which is GABA mediated.Muscle relaxation 
produced by midazolam is due to potentiation of glycine action on the anterior horn cells. 
PHARMACODYNAMICS:
CENTRAL NERVOUS SYSTEM: 
Midazolam has anxiolytic, hypnotic, anticonvulsant,muscle relaxant and anterograde amnestic 
properties. It decreases the cerebral metabolic rate and cerebral blood flow. Cerebral perfusion pressure 
decrease as the systemic pressure falls more than the intracranial pressure. Given in doses of 0.25mg/kg 
it does not alter intracranial tension and therefore it can be used for neurosurgical procedures. 
Emergence from induction is more rapid than diazepam, but not so, when compared with thiopentone. 
Midazolam decreases the anaesthetic requirement of inhalational agents.
CARDIOVASCULAR SYSTEM: 
Midazolam decreases the myocardial contractility and systemic vascular resistance and causes 
vasodilatation,thus causing fall in arterial pressure. The fall in blood pressure is similar to that caused 
by hypnotic doses of thiopentone, greater than that caused by equipotent doses of diazepam and less 
than that caused by propofol. It increases the heart rate . Midazolam does not abolish the stress 
response to intubalion, but the increase in heart rate and blood pressure are less than seen with 
diazepam.  Midazolam does not alter coronary vascular resistance and does not cause coronary steal 
phenomenon.
RESPIRATORY SYSTEM: 
Midazolam causes dose dependent depression of ventilation. In doses used for premedication or 
sedation, it does not alter the carbondioxide response,but in doses above 0.2mg/kg it causes respiratory 
depression,  Apnoea produced by midazolam is dose related and is more common in patients 
premeditated with opioids, in chronic obstructive pulmonary disorder patients, and following faster 
injection of the drug,  Their respiratory depression is reversed by flumazenil but not by naloxone. 
INTRATHECAL MIDAZOLAM:
Spinal midazolam produces analgesia by binding to specific benzodiazepine  receptors in the 
dorsal horn of the spinal cord. Muscle relaxation is by potentiating the effect of glycine which is an 
inhibitory neurotransmitter to the anterior horn cells.   
IN VITRO CHANGES IN TRANSPARENCY AND pH OF CSF CAUSED BY ADDING 
MIDAZOLAM:
CSF pH was decreased below 7.0 by adding more than 3mg of midazolam. CSF transparency 
was decreased by adding more than 7mg of midazolam. Midazolam in saline neither decreased the pH 
nor reduced the transparency. The pharmacokinetics of intrathecal midazolam depend on the molecular 
weight, lipid solubility and the systemic vascular absorbtion. 
ANTAGONIST OF MIDAZOLAM:
Flumazenil is an imidazo benzodiazepine, with specific benzodiazepine antagonist activity. 
Flumazenil binds with high affinity to specific sites when it competitively antagonizes the binding and 
allosteric effects of benzodiazepine. The intravenous administration of 0.3 to 1mg of flumazenil is 
usually sufficient to abolish the effects of therapeutic doses of benzodiazepines within 1to2 minutes. 
Additional doses may be required after 1 to 2 hours. 
USES OF MIDAZOLAM:
Premedication dose is 0.05 mg/kg to 0.1 mg/kg intramuscularly or 10-15 mg per oral. It has predictable 
absorption after intramuscular injection. It produces amnesia, anxiolysis and sedation . 
1. Intravenous sedation dose is 0.05 mg/kg to 0.1mg/kg .Sedation occurs without loss of airway 
reflexes, causes no vomiting and post operative drowsiness is less.
2. Induction dose is 0.15mg/kg to 0.3mg/kg and induction is faster than with diazepam.
3. DAY CARE SURGERY: Because of rapid onset and brief half-life midazolam is a suitable 
drug. But patients should not drive vehicles for at least eight hours as midazolam affects 
psychomotor function and postoperative instructions should be written down.
      5.   Midazolam can be used as treatment of emergence phenomenon 
DRUG INTERACTIONS:  
Erythromycin,clarithromycin and flucanozole increase the effect of midazolam due to inhibition of 
cytochrome P450 III A enzyme. H2 receptor antagonist also inhibit cytochrome P450 III A enzyme. 
Asprin and probenecid increase the effect by competing for protein binding site. Phenytion, rifampicin 
and xanthines decrease the efficacy of midazolam due to increased metabolism by inducing 
cytochrome P 450. 
SIDE EFFECTS: 
Nausea and vomiting are minimal. Incidence of hiccough is 5.6%, cough is 1.5%.
MATERIALS AND METHODS
The study was conducted in 120 patients posted for elective surgeries after getting approval of 
ethical committee of department of Anaesthesiology,  Government Rajaji Hospital and Madurai 
medical college,Madurai. Informed consent was obtained after explaining the procedure.
INCLUSION CRITERIA:
- Adult patients aged 20 – 55 yrs 
- ASA physical status I and II
- Cases like lower abdominal surgeries and gynaecological   surgeries 
EXCLUSION CRITERIA: 
- ASA physical status  III and IV.
- Allergy to local  anaesthetics .
- patients who were converted to general anaesthesia.
Palients are grouped into three groups Group B, Group M and Group F. Each group has 40 
patients. All the patients received injection Atropine 0.6 mg intramuscularly 45 minutes before 
induction.
           Group B – received 15mg of 0.5% hyperbaric bupivacaine and 0.5ml of 0.9% sodium chloride 
solution. 
Group M -  received 15mg of 0.5% hyperbaric bupivacaine and 1mg (0.2ml)of preservative free 
midazolam and 0.3 ml of 0.9% Sodium chloride solution. 
Group F – received 15 mg of 0.5  hyperbaric bupivacaine and 25mcg (0.5ml) of fentanyl . 
Total drug volume in all the three groups is 3.5ml
PROCEDURE:
Patients were explained about the procedure 
Base  line pulse rate, blood pressure and respiratony rate were recorded. 
Intravenous line was secured with 18 G canula.Preloading was done with 15- 20ml / kg of 
crystalloid solution. The following emergency drugs and equipment were kept ready. 
- Boyle`s anaesthetic  machine with oxygen cylinder. 
- Laryrgoscope with varied blades 
- Oropharyngeal airway.  
- Endotracheal tubes 
- Suction apparatus
- Drugs like atropine, adrenaline, ephedrine, dexamethasone, deriphylline, dopamine and 
naloxone. 
Patients were put on  right lateral position, under strict aseptic precaution. Subarachnoid block 
was performed using 23G Quinke Babcock`s needle in L3 – L4 interspaces. After ensuring free flow of 
CSF the drug was injected as per the group assigned. After injecting the drug patients were turned 
supine. 
RECORDING DATA:
The following were recorded 
1. Time of institution of subarachnoid  block 
2. Maximum level of sensory block achieved (which is tested by pinprick)
3. Time of onset of the maximum level of sensory block 
4. Time of onset of the  of surgery 
5. Pulse rate, blood pressure, respiratory rate and oxygen saturation were monitored every 5 
minutes for the first 15 minutes, threreafter every 10 minutes for rest of the surgery and 
every half an hour in the post operative period.
6. Hypotension was said to have occurred, if there was a fall in blood pressure 30% from the 
baseline. This was treated with 100% oxygen through face mask, intravenous fluids and 
ephedrine in titrated doses. 
7. Discomfort, if any, experienced by the patient during surgery was recorded in the 
intraoperative period by sedation scale.
SEDATION SCALE
i. Patient awake anxious and agitated 
ii. Patient awake oriented and tranquil 
iii. Patient asleep but responds to commands only 
iv. Patient asleep but responds briskly to light glabellor tap or loud auditory 
stimuli. 
v. patient asleep but responds sluggishly to light glabellor tap or loud auditory 
stimuli. 
vi. Patient  asleep with no response to stimuli. 
8. Occurence of pruritus was noted 
9. Two segment regression time (i.e) the time taken to decrease from maximum sensory level 
by two segment from the initial level noted.
10.ANALGESIA: 
Pain in the post oprative period was evaluated using word category scale 
Contant worst  pain 4 
Severe  pain 3
Moderate pain 2
Mild pain 1
No pain 0
Supplementary analgesia was given if the patient developed moderate pain 
during the post operative period. The duration of analgesia was taken as the time 
between the institution of subarachnoid block and analgesic requirement.
11. In the post operative period patients were followed up for any complication like respiratory 
depression,post operative nausea and vomiting. 
The statistical significance was brought by student t test .
OBSERVATION  AND  RESULTS
The following observations were made during the intraoperative and post operative period.
DEMOGRAPHIC DATA:
The three study groups were compared with respect to age, weight, baseline vital parameters 
and  duration of surgery . 
DEMOTGRAPHIC DATA
SL.No. Groups Age (in years)
Base line
PR (perm in) Bp (mm Hg)
1. B 42.95 ±8.86 87± 4.89
118.25/ 75.75±
18.23 / 5.04
2. M 41.48±  9.77 87.58± 5.44 119.5 /75.5 ±7.68 / 5.06
3. F 38.01± 10.02 93.00± 5.4 118.3/78.7± 8.39/5.05
HIGHEST DERMATOME LEVEL ACHIEVED :
The maximum level of sensory block achieved was elicited with pinprick. The maximum level 
achieved in each group was: 
Group ‘B’ : No patients had sensory block up to T4 and T5 
10% of patients had sensory  block up to T6
37.5% of patients had sensory block up to T7
40% of patients had sensory block up to T8 
75% of patients had sensory block up to T9
5% of patients had sensory block up to T 10
Group M : 5% of patients had sensory block up to T4
7.5% of patients had sensory block up to T5
32.5% of patients had sensory block up to T6
25% of patients had sensory block up to T7    
20% of patients had sensory block up to  T8
5% of patients had sensory block up to T9
5% of patients had sensory block up to T10
Group F : 30% of patients had sensory block up toT4
25% of patients had sensory block up to T5
22.5% of patients had sensory block up to T6
12.5% of patients had sensory block up to T7
5% of patients had sensory block up to T8
No patients had sensory block up to T9 and T10
TIME OF ONSET:
The time taken to reach the maximum sensory block was as follows
 
Group B : 7.35 Mins  ± 1.33
Group M : 4.55 Mins  ± 1.28
Group F : 4.03 Mins  ± 0.97
TWO SEGMENT REGRESSION TIME:
The average two segment regression time in each group was
 
Group B : 96.28  Mins  ±  17.84
Group M : 141.63 Mins  ±  15.87
Group F : 190.75 Mins  ± 18.18
DURATION OF ANALGESIA:
The mean deviation of analgesia was 
Group B : 145.55 Mins  ± 16.69
Group M : 195.08 Mins  ± 19.72
Group F : 253.63 Mins ± 26.79
INCIDENCE OF SIDE EFFECTS:
HYPOTENSION:
The incidence of hypotension and vasopressor requirement in each group was.
Group B : 10% of patients got hypotension
Group M : 10% of Patients got hypotension
Group F : 20% of Patients got hypotension
BRADYCARDIA:
The incidence of bradycardia (ie. pulse rate less than 60 per minute)
Group B : 5% of Patients got bradycardia
Group M : 2.5% of Patients got bradycardia
Group F : 10% of Patients got bradycardia
RESPIRATORY DEPRESSION:
Respiratory depression is set to have occurred if respiratory rate was less than 10 per minute. 
One patient in Group F had respiratory depression and required oxygen supplementation.
SEDATION SCALE:
The sedation scale for each group was
Group B 10% of patients had sedation score of 1
75% of patients had sedation score of 2
15% of patients had sedation score of 3
Group M 12.5% of patients had sedation score of 2
47.5% of patients had sedation score of 3
40% of patients had sedation score of    4
Group F Only 5% of patients had sedation score of 2
37.5% of patients had sedation score of 3
52.5% of patients had sedation score of 4
50% of patients had sedation score of  5.
DISCUSSION
The international  Association  and Society for  Pain  (IASP)  defines  pain  as  “An unpleasant 
sensation and emotional experience associated with actual or potential tissue damage or described in 
terms of such damage”.
It has also been defined by Sherington in 1906 as “The physical adjunct of protective reflex”.
Opioids have been used for pain relief since time immemorial and are still considered the gold 
standard analgesic medication.  The advances in pain relief  with opioids includes the discovery of 
newer drugs and the use of various routes of administration of the drug.  In addition to the conventional 
oral,  sublingual,  intramuscular  and  intravenous  routes  opioids  and  benzodiazepines  are  also 
administered into the central neuraxis. The neuraxial adjuvants like opioids and benzodiazepines are 
becoming increasingly popular because of their prolonged duration of action, minimal incidence of side 
effects and good intraoperative comfort.
Spinal  anesthesia  continues  to  be  the  commonly used  anesthetic  technique  in  our  country. 
Hence the addition of the adjuvants to the local anaesthetic becomes easier.
Among the opioids, lipophilic drugs  are safer within the central  neuraxis as their  cephalad 
spread is restricted. On administration into the CSF, the opioid gets attached to the spinal cord opioid 
receptor and produce their  effect.  Among the benzodiazepines,  only the midazolam is  used within 
central neuraxis.  It produces analgesia by binding to the specific benzodiazepine receptor in the dorsal 
horn of the spinal cord.  
This  is  the  study  to  evaluate  and  compare  the  intrathecally  administered  fentanyl  and 
midazolam in their post operative analgesia and intraoperative comfort.
Major advantages have been observed with four parameters.
1. Time of  onset:
The time required to achieve the maximum level of block has been shortened with the addition 
of midazolam and fentanyl but more so with fentanyl. The p value for time of onset is found to be.
0.000001 on comparing group B and group M
0.000001 on comparing group B and group F 
0.0439 on comparing group M and group F
Since p value is less than 0.05, this faster onset of action is found to be statistically significant.
2. Two segment regression time:
The two segment  regression time is  prolonged in  both adjuvant  groups  compared with the 
control group in a statistically significant manner.  The p value for two segment regression time is 
found to be.
0.00001 on comparing group B and  group M
0. 0000001 on comparing group B and group F
0. 000001 on comparing group M and group F
3. Duration of analgesia:
Duration  of  analgesia  has  been  shown  to  be  prolonged  with  the  addition  of  the 
midazolam and fentanyl.  Fentanyl scores over midazolam in duration of analgesia in a statistically 
significant manner. The p value has been found to be
0.00001 on comparing group B and group M
0.0000001 on comparing group B and group F
0. 000001 on comparing group M and group F
Groups
Time of onset 
(Minutes)
Two segment regression 
time (Minutes)
Duration of analgesia 
(Minutes)
B 7.35 + 1.33 96.28 + 17.84 145.55 + 16.69
M 4.55 + 1.28 141.63 + 15.87 195.08 + 19.72
F 4.03 + 0.97 190.75 + 18.18 253.63 + 26.79
Comparison
B and M  t
p
9.5396
0.000001
12.0122
0.000001
12.1253
0.00001
B and F  t
p
12.7556
0.000001
23.4572
0.000001
21.6565
0.0000001
M and F t
p
2.0475
0.0439
12.8733
0.000001
11.1318
0.000001
INTRAOPERATIVE COMFORT:
Intraoperative comfort here denotes mainly the absence of discomfort during manipulation of 
viscera (uterus & bowel) and patient sedation.
On comparing sedation level intraoperatively with midazolam and fentanyl, they are statistically 
significant.  p value on comparing group M and group F is 0.0261 which is significant. This shows that 
patients who received fentanyl were more comfortable than those of midazolam group.
SIDE EFFECTS:
On comparing fentanyl  and midazolam with respect   to  their  side effects  like hypotension, 
bradycardia and respiratory depression, the incidence of hypotension and bradycardia is 2 times more 
with fentanyl group than with midazolam group and one patient got respirtory depression in fentanyl 
group which was not present in midazolam group. Pruritus was not reported in any case.
So midazolam group patients were hemodynamically stable compared with fentanyl.
               
CONCLUSION
From this study comparing the midazolam and fentanyl in intrathecal administration shows that 
- The  addition  of  fentanyl  and  midazolam  gives  better  intraoperative  comfort  and  post 
operative analgesia than local anaesthetic bupivacaine. But the fentanyl gives more comfort 
and prolonged duration of analgesia than midazolam.
- The midazolam gives more hemodynamic stability than fentanyl group, by less incidence of 
hypotesion and bradycardia.
- The  sedation  without  desaturation  is  a  welcome effect  in  the  immediate  post  operative 
period with midazolam. 
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PROFORMA
COMPARATIVE STUDY OF INTRATHECAL MIDAZOLAM WITH 
INTRATHECAL FENTANYL IN COMBINATION WITH 
BUPIVACAINE
NAME:                                             AGE/SEX:                 IP NO.:                 DATE:
WEIGHT:                                            ASA RISK:
DIAGNOSIS:
GROUP M                 1mg Midazolam+3ml Bupivacaine+0.3ml 0.9%Nacl
GROUP B                  3ml Bupivacaine+0.5ml 0.9%Nacl
GROUP F                  25microgm Fentanyl+3ml Bupivacaine
Time of Spinal block:
Space of Spinal block:
Needle type & size:
Composition of drug:
Onset of spinal block (pinprick):                                  (0) Normal sensation
                                                                                      (+) pinprick recognized as touch
                                                                                      (++) no perception of touch
Level of Spinal block (pinprick):
(max. level by no perception of touch
Time of Starting of Surgery :
Baseline : Pulserate : Blood Pressure :
Monitoring: every 5 mins for 15 mins then every 10 mins for rest of surgery
TIME HR BP RR SpO2
Duration of Surgery:
Time of 2 segment regression of spinal block:
Postoperative follow up    -    Duration of absolute postoperative analgesia:
TIME RR WCS LEVEL OF SB SEDATION RESIDUAL 
ANALGESIA
WORD CATEGORY SCALE
                                  CONSTANT PAIN            4
                                  SEVERE PAIN                  3
                                  MODERATE PAIN           2
                                  MILD PAIN                       1
                                  NO PAIN                           0
SEDATION SCALE
1. awake,anxious,agitated
2. awake,oriented,tranquil
3. awake but responds to commands only
4. asleep but responds briskly to light glabellar tap or loud auditory stimuli
5. asleep but responds sluggishly to light glabellar tap or loud auditory stimuli
6. asleep no response to stimuli
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1 43 M 6 8 66 110 60 16 99 2 105 155 nil
2 28 M 7 7 70 110 60 14 99 2 95 148 nil
3 36 F 5 7 70 93 56 16 98 2 88 143 Hypotension
4 53 M 6 9 70 100 70 16 98 3 102 136 Nil
5 55 M 9 7 58 100 60 14 94 3 130 184 Nil
6 45 M 5 8 67 100 60 16 94 2 100 135 Nil
7 54 F 6 8 80 100 70 16 98 2 75 142 Nil
8 39 M 7 10 90 110 70 16 99 1 64 120 Nil
9 41 F 5 8 90 100 60 14 98 2 108 142 Nil
10 48 F 6 8 80 110 60 16 99 2 124 165 Nil
11 44 F 7 6 62 90 50 14 98 2 108 160 Nil
12 52 M 7 7 72 104 54 14 96 1 72 108 Hypotension
13 53 F 7 7 70 108 60 14 94 2 120 152 nil
14 28 F 7 8 70 100 60 14 98 2 96 140 nil
15 32 M 8 7 84 110 60 18 98 3 98 140 nil
16 42 F 7 7 66 100 60 14 98 2 92 145 nil
17 46 M 6 9 80 100 60 16 96 2 105 145 nil
18 34 M 7 6 70 120 60 18 96 2 100 165 nil
19 36 M 7 7 76 120 60 16 98 2 155 140 nil
20 32 M 7 7 80 100 60 16 96 2 90 135 nil
21 39 F 8 8 90 104 60 14 96 2 75 120 nil
22 46 F 9 8 92 106 56 14 96 2 100 160 nil
23 40 F 6 8 74 100 70 16 97 2 110 165 nil
24 55 F 9 9 60 120 60 26 94 1 70 105 nil
25 54 F 9 7 72 80 56 16 94 2 105 150 Hypotension
26 38 F 7 7 74 90 60 14 97 2 100 140 nil
27 53 M 6 8 74 98 60 16 99 2 75 145 nil
28 55 F 8 7 60 110 60 16 98 3 85 140 nil
29 46 F 10 8 58 110 60 16 96 3 95 160 bradycardia
30 47 M 8 8 64 104 60 16 98 2 105 155 nil
31 41 M 8 8 72 100 60 16 96 2 75 150 nil
32 38 F 9 7 80 120 60 18 98 2 90 145 nil
33 40 F 7 6 54 90 60 14 96 2 82 130 bradycardia
34 46 M 8 6 64 84 55 16 98 2 106 180 Hypotension
35 54 M 8 8 80 100 80 16 96 2 96 165 nil
36 53 F 10 8 82 100 70 14 95 3 75 132 nil
37 48 F 10 10 90 110 70 14 99 2 80 160 nil
38 32 F 8 8 72 100 70 16 98 2 105 140 nil
39 26 M 7 7 74 100 60 18 98 1 90 130 nil
40 26 M 7 7 62 110 70 16 96 2 105 150 nil
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1 50 M 3 6 80 100 80 12 99 3 110 190 nil
2 55 M 3 7 76 100 60 14 98 3 135 190 nil
3 32 M 4 8 76 90 54 12 96 3 140 205 nil
4 51 F 3 7 95 90 54 16 96 2 140 195 nil
5 29 M 8 8 96 100 80 16 98 3 120 225 nil
6 35 F 5 10 92 110 80 16 98 2 100 180 nil
7 55 M 6 7 76 110 80 16 99 2 125 205 nil
8 37 M 4 9 80 100 70 16 98 2 140 225 nil
9 42 F 4 10 90 110 70 16 99 2 120 200 nil
10 45 F 3 9 90 100 60 16 98 3 140 190 nil
11 36 F 5 8 84 100 70 16 98 2 125 205 nil
12 28 F 5 6 50 100 64 12 92 3 145 190 Bradycardia
13 27 M 4 8 64 100 62 10 94 4 160 205 nil
14 52 M 5 6 64 84 54 10 96 4 165 225 Hypotension
15 46 F 5 7 68 90 60 14 96 3 170 220 nil
16 44 F 5 6 72 94 62 14 96 3 135 225 nil
17 31 F 3 8 70 98 60 12 98 3 145 200 nil
18 32 F 4 6 60 100 90 14 98 3 150 198 nil
19 45 M 4 4 58 94 62 12 94 4 135 190 nil
20 54 M 5 5 60 90 60 10 92 4 130 225 Respiratory 
depression
21 52 M 5 6 72 84 54 12 96 4 135 180 Hypotension
22 28 F 4 4 76 96 60 12 98 4 140 185 nil
23 29 F 3 7 90 100 60 14 98 3 160 180 nil
24 46 F 6 8 88 100 70 14 96 3 155 200 nil
25 47 M 3 6 80 90 60 16 98 4 165 190 nil
26 33 M 4 5 90 110 90 14 97 4 135 180 nil
27 46 F 5 7 64 100 60 14 98 3 145 200 nil
28 48 F 4 6 68 104 64 14 97 4 130 165 nil
29 54 F 4 6 80 100 60 14 96 4 145 190 nil
30 51 F 4 6 86 110 60 14 97 3 145 175 nil
31 53 M 5 7 90 120 60 12 96 3 125 180 nil
32 42 F 8 6 70 110 60 14 97 4 145 205 nil
33 26 M 6 5 76 80 46 12 98 4 155 190 Hypotension
34 28 M 6 6 82 84 64 12 96 4 150 190 Hypotension
35 29 M 7 7 90 100 70 12 98 3 160 205 nil
36 42 M 4 8 80 110 70 12 96 3 130 180 nil
37 41 M 4 7 70 100 60 12 97 4 150 215 nil
38 52 M 3 7 80 100 60 10 96 3 175 205 nil
39 54 F 4 8 88 110 70 12 98 3 145 120 nil
40 32 F 5 6 90 90 60 12 97 4 145 180 nil
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1 42 F 3 5 60 100 65 12 96 4 190 240 nil
2 35 F 4 4 70 90 60 14 96 4 115 230 nil
3 27 F 4 6 80 98 71 14 96 4 105 255 nil
4 45 M 4 4 64 90 70 10 92 5 195 285 Respiratory
depression
5 52 M 3 5 60 80 54 12 94 4 190 260 Hypotension
6 26 M 4 6 70 98 60 14 96 3 198 240 nil
7 41 F 3 4 72 100 60 12 94 3 208 250 nil
8 38 F 5 5 76 100 64 12 98 4 200 265 nil
9 54 M 5 7 70 100 60 12 99 4 180 240 nil
10 56 F 6 7 84 90 60 12 96 2 185 225 nil
11 42 F 3 6 50 100 60 12 92 4 225 310 Bradycardia
12 36 M 4 6 70 90 60 14 94 3 195 245 nil
13 37 M 4 8 80 100 60 14 98 3 220 265 nil
14 27 M 3 7 68 110 70 14 96 2 124 230 nil
15 24 M 3 6 64 88 54 12 96 4 190 250 Hypotension
16 28 F 3 4 50 90 60 12 92 4 195 270 Bradycardia,
Hypotension
17 32 M 5 5 60 90 60 8 88 5 220 295 respiratory
depression
18 42 F 3 5 64 100 60 18 98 4 180 250 nil
19 51 F 4 6 66 90 60 12 96 3 190 235 Hypotension
20 38 F 4 6 70 94 64 12 99 3 195 225 nil
21 46 F 4 6 74 96 68 14 96 4 225 270 nil
22 55 M 6 5 90 90 54 14 96 4 220 280 Hypotension
23 25 M 6 4 92 100 60 12 90 3 230 270 nil
24 31 F 5 4 70 110 60 12 96 3 190 240 nil
25 29 F 5 4 74 100 60 12 94 3 180 250 Hypotension
26 26 M 5 5 88 92 60 14 94 3 165 195 Hypotension
27 36 M 5 5 92 92 60 14 99 4 200 270 nil
28 34 M 4 4 90 100 60 10 97 4 210 310 nil
29 33 M 4 4 70 110 70 12 96 4 225 315 nil
30 28 M 3 6 74 100 64 14 99 4 190 260 nil
31 45 F 3 8 80 110 70 16 100 3 150 200 nil
32 50 M 4 7 60 110 70 14 100 3 200 250 nil
33 55 M 3 6 50 100 64 14 99 3 215 265 Bradycardia
34 52 M 4 7 60 100 64 16 100 3 200 240 nil
35 53 F 6 4 50 88 54 12 96 4 215 250 Bradycardia,
Hypotension
36 33 F 3 5 70 100 58 14 98 4 190 270 nil
37 31 F 3 6 72 100 70 16 98 3 190 260 nil
38 28 M 3 4 72 100 60 16 96 4 180 220 nil
39 29 M 4 5 70 100 60 14 96 4 190 240 nil
40 32 M 4 4 80 94 60 12 96 4 165 225 nil
